Mark A. Dickson

11.7k citations
141 papers · 6.9k · 2 hit papers · h-index 37

Impact in

  • Oncology top 0.5%
    • Cancer Immunotherapy and Biomarkers
    • Cancer-related Molecular Pathways
    • CAR-T cell therapy research
    • Vascular Tumors and Angiosarcomas
    • Sarcoma Diagnosis and Treatment
    • Advanced Breast Cancer Therapies

Papers in

    • Vascular Tumors and Angiosarcomas 25
    • CAR-T cell therapy research 19
    • Cancer Immunotherapy and Biomarkers 14
    • Cancer-related Molecular Pathways 14
    • Sarcoma Diagnosis and Treatment 45
    • Advanced Breast Cancer Therapies 15

Mark A. Dickson

133 papers receiving 6.8k citations

Mark A. Dickson's Hit Papers

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center 2015 · 808 citations
8080+8+17Years since publication250500750

Peers

Mark A. Dickson
Comparison fields: 5 of 160
  • Oncology 3.7k
  • Pulmonary and Respiratory Medicine 2.5k
  • Gastroenterology 250
  • Genetics 468
  • Immunology 888
Replace Claudio Ceccarelli with:
Claudio Ceccarelli Italy
Bert H. O’Neil United States
Silvano Bòsari Italy
Grace Kim United States
Mohammed Milhem United States
David J. Vaughn United States
Anna K. Nowak Australia
Alejandro Mohar Mexico
Rifat Hamoudi United Kingdom
Ning Lü China
Mark A. Dickson relative to Claudio Ceccarelli Italy Claudio Ceccarelli's profile →
Citations per field
00.5×1.5×2.4×
Claudio Ceccarelli · 1×
Citations per year

Countries citing papers authored by Mark A. Dickson

Since Specialization
Citations

This map shows the geographic impact of Mark A. Dickson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Dickson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Dickson more than expected).

Fields of papers citing papers by Mark A. Dickson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Dickson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Dickson. The network helps show where Mark A. Dickson may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark A. Dickson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark A. Dickson Line = papers co-authored together Mark A. Dickson links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 141 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Human Keratinocytes That Express hTERT and Also Bypass a p16INK4a-Enforced Mechanism That Limits Life Span Become Immortal yet Retain Normal Growth and Differentiation Characteristics
Hit paper breakdown →
2000874
2
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Hit paper breakdown →
2015808
3 1994364
4 2013317
5 2014237
6 2011221
7 2016220
8 2016215
9 2014195
10 2009194
11 2015163
12 2013143
13 2011132
14 2013116
15 2013107
16 2017105
17 2015102
18 2016101
19 2021100
20 201698

About Mark A. Dickson

Mark A. Dickson is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Pathology and Forensic Medicine and Physiology, having authored 141 papers that have together received 6.9k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (45 papers), Vascular Tumors and Angiosarcomas (25 papers), CAR-T cell therapy research (19 papers), Advanced Breast Cancer Therapies (15 papers), Cancer Immunotherapy and Biomarkers (14 papers), Cancer-related Molecular Pathways (14 papers), Gastrointestinal Tumor Research and Treatment (12 papers) and Cardiac tumors and thrombi (11 papers). The work is most often cited by research in Oncology (3.7k citations), Pulmonary and Respiratory Medicine (2.5k citations), Gastroenterology (250 citations), Genetics (468 citations) and Immunology (888 citations). Mark A. Dickson has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Gary K. Schwartz, Sandra P. D’Angelo, Richard D. Carvajal, William D. Tap, Mary Louise Keohan, Cristina R. Antonescu, Aimeé M. Crago, Samuel Singer, Mrinal M. Gounder and James G. Rheinwald. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, The Oncologist, European Journal of Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact